Oradin60 ml

Allergic Rhinitis

Oradin is an established, guideline-supported treatment for the relief of symptoms associated with seasonal (hay fever) and perennial allergic rhinitis, including sneezing, runny nose, itchy or watery eyes, and itching of the nose or throat. Oradin works alone (monotherapy) for these symptoms and does not require combination therapy for typical seasonal or perennial allergic rhinitis.

Chronic Urticaria (Hives)

Oradin is established and guideline-recommended as a first-line option for chronic idiopathic urticaria, reducing the number, size, and itch of hives. Some patients with inadequate response may require dose adjustment or add-on therapy under a doctor's supervision (requires-combination-therapy in refractory cases) — this is a decision for the prescribing physician, not a self-directed change.

Other Allergic Skin Conditions

Oradin may provide adjunct symptomatic relief of itching in other allergic skin conditions, but Oradin is not a primary treatment for the underlying skin disease itself and should be used alongside, not instead of, condition-specific therapy directed by a doctor.

Off-Label Uses

Oradin has limited off-label use (for example, adjunct management of certain drug-induced skin reactions or bone pain associated with certain treatments), based on small studies or case reports only; these uses are not FDA-approved and should only be considered under specialist guidance.

• Oradin tablets can be taken with or without food, generally at the same time each day.
• Swallow the tablet with a glass of water; an orally disintegrating tablet form, if dispensed, should be allowed to dissolve on the tongue rather than chewed or swallowed whole.
• Oradin oral suspension should be measured using the calibrated device provided, not a household spoon.
• Do not take more than one dose of Oradin in a 24-hour period unless a doctor has directed otherwise.
• If a dose of Oradin is missed, take the missed dose when remembered unless the next scheduled dose is almost due; do not double the dose.

• CYP3A4/CYP2D6 inhibitors (e.g., ketoconazole, erythromycin, cimetidine): these medicines can raise blood levels of Oradin by inhibiting the liver enzymes that break Oradin down; in clinical studies this increased Oradin plasma concentrations without a corresponding increase in sedation or other adverse effects, but caution and medical advice are still recommended when combining these agents with Oradin.
• Central nervous system depressants (e.g., benzodiazepines, opioids, sedating antihistamines, alcohol): although Oradin itself is minimally sedating, combining Oradin with other CNS depressants may still add to drowsiness in some individuals, and caution is advised.
• Other H1-antihistamines or histamine-based therapies: combining Oradin with other antihistamine products is generally unnecessary and can increase the risk of side effects without added benefit; discuss any such combination with a doctor or pharmacist.

Common Side Effects

Headache, dry mouth, fatigue or tiredness, and gastrointestinal upset (such as nausea, abdominal discomfort) have been reported with Oradin, generally at rates similar to placebo in clinical trials. Mild drowsiness can occur in some people even though Oradin is classed as non-sedating.

Serious Side Effects — Seek Medical Attention

Seek prompt medical attention if any of the following occur with use of Oradin: signs of an allergic reaction (rash, hives, swelling of the face/lips/tongue/throat, difficulty breathing); fast or irregular heartbeat; or fainting. These reactions are uncommon but require urgent evaluation. See Precautions and Warnings and Overdose Effects for further detail.

Pregnancy

Human pregnancy data on Oradin are more extensive than for many other allergy medicines and are generally reassuring: several cohort and case-control studies, including large birth-defect surveillance data, have not found an increased risk of major birth defects (including an earlier reported hypospadias signal that was not confirmed in later, larger studies) or of miscarriage with first-trimester use of Oradin. This differs from some older manufacturer labeling that classified Oradin use in pregnancy as “not recommended unless clearly needed” based on limited data available at the time. Oradin should still only be used in pregnancy if a doctor decides Oradin is needed, since no medicine can be called completely risk-free in pregnancy.

Breastfeeding

Oradin and desOradin, the active metabolite of Oradin, pass into breast milk in small amounts. Available data suggest the amount is too low to be expected to cause problems in most breastfed infants, and Oradin is often considered a preferred antihistamine choice during breastfeeding because Oradin is less sedating than older agents. There is a theoretical possibility that Oradin, particularly combined with other medicines, could reduce milk supply in some mothers; a doctor should be consulted, especially if milk supply concerns arise.

• Liver or kidney disease: Oradin is broken down by the liver and cleared partly by the kidneys, so patients with significant hepatic impairment or severe renal impairment may need a reduced dosing frequency; consult a doctor before use — see Use in Special Populations.
• Driving or operating machinery: although Oradin is classed as non-sedating and has performed comparably to placebo on driving and psychomotor tests in studies, individual sensitivity varies, and caution is advised until a person knows how Oradin affects them.
• Known allergy to antihistamines: people with a prior allergic reaction to Oradin or similar antihistamines should avoid Oradin and inform their doctor or pharmacist.
• Use in young children: safety and effectiveness of Oradin have not been well established in children younger than 2 years; use in this age group should only occur under a pediatrician's direction — see Use in Special Populations.
• Self-medication limits: if allergy symptoms do not improve after several days of Oradin use, or worsen, or are accompanied by fever, a doctor should be consulted rather than continuing to increase or extend Oradin use on one's own.

Reported effects of Oradin overdose in adults have most commonly included drowsiness, fast heartbeat (tachycardia), and headache. In children, overdose has been associated with effects such as fast heartbeat and, less commonly, movement (extrapyramidal-type) symptoms; most reported pediatric ingestions have caused only mild, transient changes in vital signs. Do not induce vomiting unless specifically directed to do so by a doctor or Poison Control. If an overdose of Oradin is suspected, contact a doctor, hospital emergency department, or a Poison Control Center immediately for guidance; treatment is generally supportive and may include activated charcoal if given soon after ingestion, under medical supervision.

Children

Oradin is approved for use from 2 years of age for allergic rhinitis and chronic urticaria, with a lower dose (5 mg once daily) used for children 2 to under 6 years and the adult dose (10 mg once daily) from 6 years. Use in children younger than 2 years is not established and should only be undertaken on a pediatrician's specific advice — see Pediatric Uses for detail.

Elderly

Studies have not shown significant differences in the effectiveness or overall safety profile of Oradin between elderly and younger adults; no routine dose adjustment based on age alone is required, though age-related decline in liver or kidney function should be considered (see Renal and Hepatic Impairment below).

Renal Impairment

In patients with severe renal impairment, clearance of Oradin and desOradin, the active metabolite of Oradin, is reduced. A reduced-frequency dosing regimen (such as giving the usual age-appropriate dose every other day) is commonly recommended in this situation, but the exact adjustment should be individualized by the prescribing doctor rather than self-directed.

Hepatic Impairment

Because Oradin is extensively metabolized by the liver, patients with significant hepatic impairment can have higher and longer-lasting blood levels of Oradin. A reduced-frequency regimen similar to that used in renal impairment is commonly recommended, under a doctor's direction.

Pregnant and Breastfeeding Women

See Pregnancy and Lactation for detailed guidance; use should be directed by a treating doctor.